ASBMB

In this exclusive launch webinar, Sumit Kalsi, Associate Director of Product Research at Nuclera, will unveil a breakthrough solution: Nuclera's Rapid Antibody Screening Service. He will demonstrate how integrating a 96-plex cell-free binary expression and yes/no binding screen can act as the ultimate early filter for your pipeline.

Join Dr. Magdalena Richter, Associate Principal Scientist at AstraZeneca, as she details how her team systematically addressed this bottleneck. By benchmarking Nuclera’s eProtein Discovery™ system against standard E. coli cell-based expression, her team asked a critical question: Can a 24-hour, cell-free screen accurately predict expression success at scale?